Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

PURPOSE: Multiple myeloma (MM) remains an incurable disease as tumor cells ultimately resist to all available drugs. Homing of tumor cells to the bone marrow microenvironment, involving especially the CXCR4/SDF-1 axis, allows them to survive, proliferate and resist to therapy. F50067, a humanized an...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouquet, Guillemette, Guidez, Stéphanie, Richez, Valentine, Stoppa, Anne-Marie, Le Tourneau, Christophe, Macro, Margaret, Gruchet, Cécile, Bobin, Arthur, Moya, Niels, Syshenko, Thomas, Sabirou, Florence, Levy, Anthony, Franques, Paul, Gardeney, Hélène, Karlin, Lionel, Benboubker, Lotfi, Ouali, Monia, Vedovato, Jean-Claude, Ferre, Pierre, Pavlyuk, Mariya, Attal, Michel, Facon, Thierry, Leleu, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963612/
https://www.ncbi.nlm.nih.gov/pubmed/29844860
http://dx.doi.org/10.18632/oncotarget.25156

Ejemplares similares

Ejemplares similares